Related Experiment Video
Updated: Nov 14, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
Antidrug Antibodies and Drug Development: Challenges in the Immunotherapy Era
Bernard Doger de Spéville1, Victor Moreno2
1Early Phase Clinical Trials Unit START-Madrid-FJD, Fundación Jiménez Diaz University Hospital, Madrid, Spain.
Abstract:
Novel antibody formats such as bispecifics have increased risk of immunogenicity, impacting safety and efficacy. LY3415244, a novel T-cell immunoglobulin and mucin-domain-containing molecule-3 (TIM3)-PDL1 (programmed death (ligand) 1) bispecific caused neutralizing antibody-drug antibodies (ADA) in 12 of 12 patients and required study termination. Novel approaches are needed to ameliorate and manage this undesirable effect of therapeutic antibodies.See related article by Hellmann et al., p. 2773.
Related Concept Videos
Cross-reactivity
Tumor Immunotherapy
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

